샘플 요청 목록

 카트 문의
시장보고서
상품코드
1576950

세계의 안과용 레이저 시장 : 인사이트, 경쟁 구도, 시장 예측(2030년)

Ophthalmic Lasers - Market Insights, Competitive Landscape, and Market Forecast - 2030
발행일: | 리서치사: DelveInsight | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

세계의 안과용 레이저 시장 규모는 2023년에 12억 5,000만 달러 되었습니다. 이 시장은 2024-2030년의 예측 기간에 6.11%의 CAGR로 확대하며, 2030년에는 17억 8,000만 달러에 달할 것으로 예측됩니다. 녹내장, 당뇨병성 망막증, 노인성 황반변성(AMD), 백내장 등 안과 질환의 유병률 증가는 안과용 레이저 시장의 주요 촉진요인입니다. 또한 회복 시간 단축, 합병증 위험 감소, 통증 감소 등의 장점으로 인해 환자와 의료 서비스 프로바이더 사이에서 최소 침습적 시술에 대한 선호도가 높아지고 있습니다. 또한 주요 시장 진출기업이 혁신적인 안과용 레이저를 도입하기 위해 연구개발에 지속적으로 투자하고, 파트너십 및 공동 연구, 제품 출시 및 승인 증가는 2024-2030년의 예측 기간 중 안과용 레이저 시장을 촉진하는 주요 요인 중 일부입니다.

세계보건기구(WHO)가 제공한 최근 데이터와 통계(2023년)에 따르면 전 세계 최소 22억 명이 근시 또는 원시 시력 장애를 경험하고 있습니다. 이 중 약 10억 명은 아직 치료되지 않은 상태입니다. 이 중 원거리 시력 장애와 실명의 주요 원인은 9,400만 명이 앓고 있는 백내장, 8,840만 명이 앓고 있는 굴절 이상, 800만 명이 앓고 있는 노화성 황반변성, 770만 명이 앓고 있는 녹내장, 390만 명이 앓고 있는 당뇨병성 망막증 등입니다. 노안은 근시 시력 장애의 주요 원인으로 8억 2,600만 명이 앓고 있습니다.

당뇨병성 망막증, 녹내장, 노인성 황반변성과 같은 질환의 발병률이 증가함에 따라 효과적이고 최소 침습적인 치료법에 대한 수요가 증가하고 있습니다. 안과용 레이저는 이러한 질환을 기존 방법보다 더 효율적으로 관리할 수 있는 정확하고 표적화된 치료법을 제공합니다. 예를 들어 당뇨망막병증과 망막정맥폐쇄증에 대한 레이저 치료는 시력 저하를 예방하고 예후를 개선할 수 있습니다. 펨토초 레이저 및 YAG 레이저와 같은 혁신적인 레이저 기술의 발전으로 치료할 수 있는 질환의 범위가 확대되고 치료 효과가 향상되었습니다.

또한 전 세계에서 제품 개발 활동이 증가함에 따라 안과용 레이저 시장 전체가 더욱 성장하고 있습니다. 예를 들어 2024년 1월, 레이저 기반 의료기기의 선도적 공급업체인 IRIDEX Corporation은 미국에서 IRIDEX 532 및 IRIDEX 577 레이저를 특징으로 하는 차세대 플랫폼을 발표했습니다. 이 첨단 레이저는 망막 질환 및 녹내장 치료를 위해 설계되었으며, 연속파 및 이리덱스의 독자적인 마이크로 펄스 기술을 포함한 다양한 치료 모드를 제공합니다. 또한 이 플랫폼은 직관적인 터치스크린 인터페이스를 통해 다양한 임상 제어 기능 및 설정에 대한 액세스를 제공하여 사용 편의성과 치료 정확도를 향상시켰습니다.

이러한 요인들은 예측 기간 중 안과용 레이저 시장을 촉진할 가능성이 높습니다.

그러나 안과용 레이저 기기 사용 후 감염 위험과 제품 승인에 대한 엄격한 규제 문제는 안과용 레이저의 미래 시장을 저해할 수 있습니다.

세계의 안과용 레이저 시장에 대해 조사했으며, 시장의 개요와 제품 유형별, 용도별, 최종사용자별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.

목차

제1장 안과용 레이저 시장 보고서 서론

제2장 안과용 레이저 시장의 개요

제3장 경쟁 구도

제4장 규제 분석

  • 미국
  • 유럽
  • 일본
  • 중국

제5장 안과용 레이저 시장의 주요 요인 분석

  • 안과용 레이저 시장 성장 촉진요인
  • 안과용 레이저 시장 성장 억제요인과 과제
  • 안과용 레이저 시장 기회

제6장 안과용 레이저 시장의 Porter's Five Forces 분석

제7장 안과용 레이저 시장 평가

  • 제품 유형별
  • 용도별
  • 최종사용자별
  • 지역별

제8장 안과용 레이저 시장의 기업과 제품의 개요

  • Alcon Inc.
  • IRIDEX Corporation
  • Alna-Medicalsystem AG & Co. KG
  • BAUSCH + LOMB INCORPORATED
  • Lumenis Be Ltd.
  • Abbott
  • NIDEK CO., LTD.
  • MERIDIAN AG
  • Johnson & Johnson Vision
  • LIGHTMED
  • ZEISS
  • Navilas Academy
  • Aeon Meditec
  • Quantel Medical
  • Lumibird Medical
  • Ziemer Ophthalmic Systems AG
  • Novartis AG
  • Lumenis
  • Canon Medical Systems
  • Optovue

제9장 KOL의 견해

제10장 프로젝트 어프로치

제11장 DelveInsight 소개

제12장 면책사항과 문의

KSA 24.10.31

Ophthalmic Lasers Market by Product Type (Argon Blue-Green Laser, ND: Yag Laser, Femtosecond Lasers, Krypton Red Laser, and Others), Application (Glaucoma, Diabetic Retinopathy, Cataracts, and Others), End-User (Hospitals, Ambulatory Surgical Centers, Ophthalmic Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2030 owing to the surge in the prevalence of ophthalmic diseases such as glaucoma, diabetic retinopathy, and others, growing preference for minimally invasive procedures, and increase in product launches and approvals by key market players across the globe.

The global ophthalmic laser devices market was valued at USD 1.25 billion in 2023, growing at a CAGR of 6.11% during the forecast period from 2024 to 2030, to reach USD 1.78 billion by 2030. The rising prevalence of ophthalmic diseases such as glaucoma, diabetic retinopathy, age-related macular degeneration (AMD), and cataracts are the major drivers for the ophthalmic lasers market. Additionally, a strong preference among patients and healthcare providers for minimally invasive procedures due to their benefits, including shorter recovery times, reduced risk of complications, and less pain. Furthermore, key market players continuously investing in research and development to introduce innovative ophthalmic lasers, increased partnerships and collaborations, product launches and approvals are some of the key factors boosting the market for ophthalmic lasers, during the forecast period from 2024 to 2030.

Ophthalmic Lasers Market Dynamics:

According to the recent data and stats provided by the World Health Organization (2023), globally, at least 2.2 billion people experienced near or distance vision impairment. Of these, approximately 1 billion cases remained unaddressed. Among this group, the leading causes of distance vision impairment or blindness included cataracts, affecting 94 million people; refractive errors, impacting 88.4 million; age-related macular degeneration, which affected 8 million; glaucoma, with 7.7 million cases; and diabetic retinopathy, affected 3.9 million. Presbyopia was the primary condition causing near vision impairment, affecting 826 million people.

Thus, as the incidence of conditions like diabetic retinopathy, glaucoma, and age-related macular degeneration rises, there is a growing demand for effective, minimally invasive treatments. Ophthalmic lasers offer precise, targeted therapies that can manage these disorders more efficiently than traditional methods. For instance, laser treatments for diabetic retinopathy and retinal vein occlusions can prevent vision loss and improve outcomes. The advancement of laser technology, with innovations such as femtosecond and YAG lasers, expanded the range of treatable conditions and enhanced procedural efficacy, driving further adoption in clinical settings and hence driving the market growth of ophthalmic laser across the globe.

Additionally, the increase in product development activities across the globe is further boosting the overall market of ophthalmic lasers. For instance, in January 2024, IRIDEX Corporation, a leading provider of laser-based medical equipment, unveiled its next-generation platform featuring the IRIDEX 532 and IRIDEX 577 lasers in the United States. These advanced lasers were designed for the treatment of retinal diseases and glaucoma, offering a range of treatment modes, including continuous-wave and IRIDEX's exclusive MicroPulse technology. The platform also boasts an intuitive touchscreen interface that provided the access to various clinical control features and settings, enhancing ease of use and precision in treatment.

Thus, the factors mentioned above are likely to boost the market of ophthalmic lasers during the forecasted period.

However, the risk of developing infection after the use of an ophthalmic laser device and stringent regulatory concerns for product approval may hinder the future market of ophthalmic lasers.

Ophthalmic Lasers Market Segment Analysis:

Ophthalmic Lasers Market by Product Type (Argon Blue-Green Laser, ND: Yag Laser, Femtosecond Lasers, Krypton Red Laser, and Others), Application (Glaucoma, Diabetic Retinopathy, Cataracts, and Others), End-User (Hospitals, Ambulatory Surgical Centers, Ophthalmic Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the ophthalmic lasers market, femtosecond lasers is projected to hold a considerable market share in 2023. Femtosecond lasers can significantly boost the ophthalmic laser market through their advanced capabilities and the benefits they offer over traditional methods. These lasers operate at incredibly short pulse durations-femtoseconds (one quadrillionth of a second)-allowing for precise and controlled tissue disruption with minimal thermal damage. This precision are particularly advantageous in delicate eye surgeries, such as cataract surgery, where femtosecond lasers are used to perform tasks like corneal incision, lens fragmentation, and capsulotomy with high accuracy. By enhancing surgical outcomes and reducing complications, femtosecond lasers contribute to better patient experiences and quicker recoveries, which in turn increases their adoption among both surgeons and patients. The technology also allows for customized treatments, as surgeons can tailor the laser's parameters to each patient's specific anatomy and condition, further improving efficacy and safety. As a result, femtosecond lasers drive market growth by expanding the range of treatable conditions, enhancing procedural success rates, and encouraging investment in advanced ophthalmic technologies. This growth is further supported by ongoing advancements in laser technology and increasing patient demand for minimally invasive, precise, and effective treatment options.

Additionally, the increasing product approval across the globe are further propelling the market of the segment. For instance, In April 2023, Johnson & Johnson Vision, a global leader in eye health and part of Johnson & Johnson MedTech received U.S Food and Drug Administration FDA 510(k) approval on their ELITA Femtosecond Laser.

Therefore, owing to the above-mentioned factors, the femtosecond lasers category is expected to generate considerable revenue thereby pushing the overall growth of the global ophthalmic lasers market during the forecast period.

North America is expected to dominate the overall Ophthalmic Lasers market:

Among all the regions, North America is expected to hold the largest share in the global ophthalmic lasers market in 2023. The ophthalmic lasers market in North America is witnessing growth due to several factors like rising incidence of eye disorders like diabetic retinopathy and glaucoma across the region. Additionally, the market is benefited from the presence of prominent industry players and ongoing product development initiatives, including new launches and regulatory approvals. These factors collectively contribute to the expansion of the ophthalmic lasers market in North America, catering to the increasing demand for advanced treatments and technologies in eye care.

According to the data provided by the Centers for Disease Control and Prevention (CDC) (2023), in 2021 it was estimated that in the United States, around 9.6 million people with diabetes, or 2.6%, have diabetic retinopathy (DR), and 1.84 million, or 5.1% of those with diabetes, had vision-threatening diabetic retinopathy (VTDR). Among people over the age of 40 years with diabetes, approximately 1 in 4 had diabetic retinopathy. The prevalence of DR is highest (28.4%) in the 65-79 age group and lowest (13.0%) in those under 25. Overall, there were 8.94 million cases of diabetic retinopathy and 1.71 million cases of vision-threatening diabetic retinopathy among people aged 40 and above. Thus, the increasing prevalence of diabetic retinopathy (DR) in North America, is driving demand for ophthalmic lasers.

Furthermore, recent merger, acquisitions, and approvals among key market players in the region further propels the market across the region. For example, in September 2023, MERIDIAN AG got the approval from the U.S. Food and Drug Administration (FDA) for their innovative Merilas product family which was developed by MERIDIAN AG for the treatment of retinal disorder and glaucoma. Therefore, increasing product approvals, and launches of the product along with the presence of key players, among others is expected to boost the growth of the ophthalmic lasers market in the North American region during the forecast period from 2024 to 2030.

Ophthalmic Lasers Market Key Players:

Some of the key market players operating in the ophthalmic lasers market include Alcon Inc., IRIDEX Corporation, Alna-Medicalsystem AG & Co. KG, BAUSCH + LOMB INCORPORATED, Lumenis Be Ltd., Abbott, NIDEK CO., LTD, MERIDIAN AG, Johnson & Johnson Vision, LIGHTMED, ZEISS, Navilas Academy, Aeon Meditec, Quantel Medical, Lumibird Medical, Ziemer Ophthalmic Systems AG, Novartis, Lumenis, Canon Medical Systems, Optovue, and others.

Recent Developmental Activities in the Ophthalmic Lasers Market:

  • In January 2024, MERIDIAN AG received the U.S. Food and Drug Administration (FDA) approval for their MR Q series, this product provided a high-quality and inventive healthcare solution that required the needs of patients and physicians around the world.
  • In March 2021, IRIDEX Corporation, announced a collaboration with Topcon Corporation a Japanese manufacturer and distributor of the eye care business to expand their market of ophthalmic lasers in Asia-Pacific.

Key Takeaways From the Ophthalmic Lasers Market Report Study:

  • Market size analysis for current ophthalmic lasers size (2023), and market forecast for 6 years (2024 to 2030)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
  • Key companies dominating the ophthalmic lasers market.
  • Various opportunities available for the other competitors in the ophthalmic lasers market space.
  • What are the top-performing segments in 2023? How these segments will perform in 2030?
  • Which are the top-performing regions and countries in the current ophthalmic lasers market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for ophthalmic lasers market growth in the coming future?

Target Audience who can be Benefited From This Ophthalmic Lasers Market Report Study:

  • Ophthalmic lasers product providers
  • Research organizations and consulting companies
  • Ophthalmic lasers -related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in ophthalmic lasers
  • Various end-users who want to know more about the ophthalmic lasers market and the latest technological developments in the ophthalmic lasers market.

Frequently Asked Questions for the Ophthalmic Lasers Market:

1. What are ophthalmic lasers?

  • An ophthalmic laser is a medical device used in eye care to perform precise and controlled procedures on the eye. It utilizes focused light beams to treat various eye conditions, including cataracts, glaucoma, and retinal disorders, by either cutting, reshaping, or stimulating tissues with minimal invasiveness.

2. What is the market for ophthalmic lasers?

  • The global ophthalmic laser devices market was valued at USD 1.25 billion in 2023, growing at a CAGR of 6.11% during the forecast period from 2024 to 2030, to reach USD 1.78 billion by 2030.

3. What are the drivers for the ophthalmic lasers market?

  • The rising prevalence of ophthalmic diseases such as glaucoma, diabetic retinopathy, age-related macular degeneration (AMD), and cataracts is a major driver of the ophthalmic laser market. Additionally, a strong preference among patients and healthcare providers for minimally invasive procedures due to their benefits, including shorter recovery times, reduced risk of complications, and less pain. Further, key market players continuously investing in research and development to introduce innovative ophthalmic lasers, increased partnerships and collaborations, product launches and approvals ensures that market remains dynamic and innovative, during the forecast period from 2024 to 2030.

4. Who are the key players operating in the ophthalmic lasers market?

  • Some of the key market players operating in the ophthalmic lasers market include Alcon Inc., IRIDEX Corporation, Alna-Medicalsystem AG & Co. KG, BAUSCH + LOMB INCORPORATED, Lumenis Be Ltd., Abbott, NIDEK CO., LTD, MERIDIAN AG, Johnson & Johnson Vision, LIGHTMED, ZEISS, Navilas Academy, Aeon Meditec, Quantel Medical, Lumibird Medical, Ziemer Ophthalmic Systems AG, Novartis, Lumenis, Canon Medical Systems, Optovue, and others.

5. Which region has the highest share in the ophthalmic lasers market?

  • North America is expected to hold the largest share in the global ophthalmic lasers market in 2023. This can be attributed to the rising incidence of eye disorders such as diabetic retinopathy and glaucoma across the region. Additionally, the market is benefited from the presence of prominent industry players and ongoing product development initiatives, including new launches and regulatory approvals. These factors collectively contribute to the expansion of the ophthalmic lasers market in North America, catering to the increasing demand for advanced treatments and technologies in eye care.

Table of Contents

1. Ophthalmic Lasers Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Ophthalmic Lasers Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Ophthalmic Lasers Market Key Factors Analysis

  • 5.1. Ophthalmic Lasers Market Drivers
    • 5.1.1. Growing prevalence of ophthalmic diseases such as glaucoma, diabetic retinopathy, and others
    • 5.1.2. Growing preference for minimally invasive procedures
    • 5.1.3. Increase in product launches and approvals by key market players across the globe.
  • 5.2. Ophthalmic Lasers Market Restraints and Challenges
    • 5.2.1. Risk of developing infection after the use of ophthalmic lasers
    • 5.2.2. Stringent regulatory concerns for product approval
  • 5.3. Ophthalmic Lasers Market Opportunities
    • 5.3.1. Integration of artificial intelligence in the field of ophthalmology lasers

6. Ophthalmic Lasers Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Ophthalmic Lasers Market Assessment

  • 7.1. By Product Type
    • 7.1.1. Argon blue-green laser
    • 7.1.2. ND: YAG Laser
    • 7.1.3. Femtosecond Lasers
    • 7.1.4. Krypton Red lasers
    • 7.1.5. Others
  • 7.2. By Application
    • 7.2.1. Glaucoma
    • 7.2.2. Diabetic Retinopathy
    • 7.2.3. Cataracts
    • 7.2.4. Others
  • 7.3. By End-User
    • 7.3.1. Hospitals
    • 7.3.2. Ophthalmic Clinics
    • 7.3.3. Ambulatory Surgical Centers
    • 7.3.4. Others
  • 7.4. By Geography
    • 7.4.1. North America
      • 7.4.1.1. United States Ophthalmic Lasers Market Size in USD Million (2021-2030)
      • 7.4.1.2. Canada Ophthalmic Lasers Market Size in USD Million (2021-2030)
      • 7.4.1.3. Mexico Ophthalmic Lasers Market Size in USD Million (2021-2030)
    • 7.4.2. Europe
      • 7.4.2.1. France Ophthalmic Lasers Market Size in USD Million (2021-2030)
      • 7.4.2.2. Germany Ophthalmic Lasers Market Size in USD Million (2021-2030)
      • 7.4.2.3. United Kingdom Ophthalmic Lasers Market Size in USD Million (2021-2030)
      • 7.4.2.4. Italy Ophthalmic Lasers Market Size in USD Million (2021-2030)
      • 7.4.2.5. Spain Ophthalmic Lasers Market Size in USD Million (2021-2030)
      • 7.4.2.6. Rest of Europe Ophthalmic Lasers Market Size in USD Million (2021-2030)
    • 7.4.3. Asia-Pacific
      • 7.4.3.1. China Ophthalmic Lasers Market Size in USD Million (2021-2030)
      • 7.4.3.2. Japan Ophthalmic Lasers Market Size in USD Million (2021-2030)
      • 7.4.3.3. India Ophthalmic Lasers Market Size in USD Million (2021-2030)
      • 7.4.3.4. Australia Ophthalmic Lasers Market Size in USD Million (2021-2030)
      • 7.4.3.5. South Korea Ophthalmic Lasers Market Size in USD Million (2021-2030)
      • 7.4.3.6. Rest of Asia-Pacific Ophthalmic Lasers Market Size in USD Million (2021-2030)
    • 7.4.4. Rest of the World (RoW)
      • 7.4.4.1. Middle East Ophthalmic Lasers Market Size in USD Million (2021-2030)
      • 7.4.4.2. Africa Ophthalmic Lasers Market Size in USD Million (2021-2030)
      • 7.4.4.3. South America Ophthalmic Lasers Market Size in USD Million (2021-2030)

8. Ophthalmic Lasers Market Company and Product Profiles

  • 8.1. Alcon Inc.
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. IRIDEX Corporation
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. Alna-Medicalsystem AG & Co. KG
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. BAUSCH + LOMB INCORPORATED
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Lumenis Be Ltd.
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Abbott
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. NIDEK CO., LTD.
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. MERIDIAN AG
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Johnson & Johnson Vision
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. LIGHTMED
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. ZEISS
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Navilas Academy
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Aeon Meditec
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Quantel Medical
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Lumibird Medical
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. Ziemer Ophthalmic Systems AG
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Novartis AG
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Lumenis
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Canon Medical Systems
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. Optovue
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제